DE602004028949D1 - Ansforming growth factor beta 1 (tgf-beta1) zu binden - Google Patents

Ansforming growth factor beta 1 (tgf-beta1) zu binden

Info

Publication number
DE602004028949D1
DE602004028949D1 DE602004028949T DE602004028949T DE602004028949D1 DE 602004028949 D1 DE602004028949 D1 DE 602004028949D1 DE 602004028949 T DE602004028949 T DE 602004028949T DE 602004028949 T DE602004028949 T DE 602004028949T DE 602004028949 D1 DE602004028949 D1 DE 602004028949D1
Authority
DE
Germany
Prior art keywords
tgf
growth factor
ansforming
binden
beta1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004028949T
Other languages
English (en)
Inventor
De Las Herrerias Javier Dotor
Vazquez Ana Belen Lopez
Sagastibelza Juan Jose Lasarte
Valtuena Jesus Prieto
Cuesta Francisco Borras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Original Assignee
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto de Biomedicina CIMA SL filed Critical Proyecto de Biomedicina CIMA SL
Publication of DE602004028949D1 publication Critical patent/DE602004028949D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602004028949T 2003-08-22 2004-07-05 Ansforming growth factor beta 1 (tgf-beta1) zu binden Active DE602004028949D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200302020A ES2304069B1 (es) 2003-08-22 2003-08-22 Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
PCT/ES2004/000320 WO2005019244A1 (es) 2003-08-22 2004-07-05 Péptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-beta1)

Publications (1)

Publication Number Publication Date
DE602004028949D1 true DE602004028949D1 (en) 2010-10-14

Family

ID=34203356

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004028949T Active DE602004028949D1 (en) 2003-08-22 2004-07-05 Ansforming growth factor beta 1 (tgf-beta1) zu binden

Country Status (18)

Country Link
US (1) US7666841B2 (de)
EP (1) EP1669367B1 (de)
JP (1) JP4902352B2 (de)
CN (1) CN100424093C (de)
AT (1) ATE479702T1 (de)
AU (2) AU2004266856A1 (de)
BR (1) BRPI0413215A (de)
CA (1) CA2535807A1 (de)
CY (1) CY1110885T1 (de)
DE (1) DE602004028949D1 (de)
DK (1) DK1669367T3 (de)
ES (2) ES2304069B1 (de)
HR (1) HRP20100637T1 (de)
PL (1) PL1669367T3 (de)
PT (1) PT1669367E (de)
RU (2) RU2333917C2 (de)
SI (1) SI1669367T1 (de)
WO (1) WO2005019244A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158589B2 (en) * 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
CN101340927A (zh) * 2005-10-24 2009-01-07 西玛生物医学信息公司 TGF-β1抑制性多肽在制备免疫反应调节剂上的用途
ES2327088B1 (es) * 2007-08-20 2010-07-26 Proyecto De Biomedicina Cima S.L. Combinaciones terapeuticas para el tratamiento de las metastasis.
ES2337973B8 (es) 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
ES2330826B1 (es) 2008-06-04 2010-07-26 Proyecto De Biomedicina Cima, S.L. Sistema para empaquetamiento de adenovirus de alta capacidad.
CN102123737B (zh) 2008-06-13 2014-01-01 西马生物医学计划公司 用于生物活性化合物施用的轭合物
US20110294734A1 (en) * 2009-02-05 2011-12-01 Digna Biotech, S.L. Pharmaceutical compositions comprising tgf-beta 1 inhibitor peptides
AU2010316996A1 (en) 2009-11-05 2012-06-14 Proyecto De Biomedicina Cima, S.L. Regulated expression systems
WO2012001196A2 (es) 2010-06-28 2012-01-05 Proyecto De Biomedicina Cima, S.L. Vectores alfavirales y usos de los mismos para la expresión de genes heterólogos
KR101029705B1 (ko) * 2010-06-30 2011-04-18 (주)엔솔테크 신규 펩타이드 및 그 용도
EP2407534A1 (de) 2010-07-14 2012-01-18 Neo Virnatech, S.L. Verfahren und Reagenzien zum Erhalt von transkriptionell aktiven virusähnlichen Artikeln und rekombinante Virionen
CA2857073A1 (en) 2011-11-28 2013-06-06 Institucio Catalana De Recerca I Estudis Avancats Methods and kits for the prognosis of colorectal cancer
WO2013113755A1 (en) 2012-01-30 2013-08-08 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Reagents and methods for the treatment of diseases based on the inhibition of calcineurin - nfat signalling pathway
EP2917365B1 (de) 2012-11-12 2020-03-11 Institució Catalana de Recerca i Estudis Avançats Verfahren und kits zur prognose von kolorektalem karzinom
US20140170158A1 (en) * 2012-12-17 2014-06-19 The Johns Hopkins University Compositions and methods for treating or preventing lung diseases
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
JP6730701B2 (ja) 2013-11-14 2020-07-29 学校法人同志社 細胞増殖促進または細胞障害抑制による角膜内皮治療薬
EP2878674A1 (de) 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Stabile Episomen auf Basis von nichtintegrativen lentiviralen Vektoren
WO2015101666A1 (en) 2014-01-03 2015-07-09 Fundación Biofísica Bizkaia VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF
US20170121685A1 (en) 2015-11-02 2017-05-04 Tigenix S.A.U. Mesenchymal stem cell-derived exosomes and their uses
WO2017110093A1 (ja) 2015-12-24 2017-06-29 学校法人同志社 ＴＧＦ－βシグナルに起因する障害を治療または予防するための医薬およびその応用
GB201707561D0 (en) * 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
WO2019022152A1 (ja) 2017-07-26 2019-01-31 学校法人同志社 ＴＧＦ－βシグナルに起因する障害を治療または予防するための医薬およびその応用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08151396A (ja) * 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US6509318B1 (en) * 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
KR20050084921A (ko) * 2002-11-01 2005-08-29 보이스 타운 내셔널 리서치 호스피탈 α１β1 인테그린에 대한 유도성 리간드 및 이의 용도

Also Published As

Publication number Publication date
US7666841B2 (en) 2010-02-23
CN100424093C (zh) 2008-10-08
PT1669367E (pt) 2010-12-07
EP1669367B1 (de) 2010-09-01
BRPI0413215A (pt) 2007-06-19
JP4902352B2 (ja) 2012-03-21
HRP20100637T1 (hr) 2010-12-31
RU2333917C2 (ru) 2008-09-20
CA2535807A1 (en) 2005-03-03
RU2455358C2 (ru) 2012-07-10
SI1669367T1 (sl) 2010-11-30
AU2010212466B2 (en) 2012-07-19
CN1839149A (zh) 2006-09-27
CY1110885T1 (el) 2015-06-10
ATE479702T1 (de) 2010-09-15
WO2005019244A1 (es) 2005-03-03
AU2010212466A1 (en) 2010-09-09
ES2304069A1 (es) 2008-09-01
ES2304069B1 (es) 2009-08-12
ES2351865T3 (es) 2011-02-11
RU2006109011A (ru) 2006-07-27
US20070142275A1 (en) 2007-06-21
PL1669367T3 (pl) 2011-02-28
AU2004266856A1 (en) 2005-03-03
DK1669367T3 (da) 2010-11-08
JP2007525204A (ja) 2007-09-06
EP1669367A1 (de) 2006-06-14
RU2008115678A (ru) 2009-10-27

Similar Documents

Publication Publication Date Title
CY1110885T1 (el) Πεπτιδια που μπορουν να συνδεθουν στον αυξητικο παραγοντα μεταμορφωσης βητα 1 (tgf-beta1)
SI1615952T1 (sl) Metoda zdravljenja vnetnih bolezni z uporabo specifičnih veznih sredstev humanega angiopoetin
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
NZ542616A (en) P38 inhibitors and methods of use thereof
HK1145692A1 (zh) 人血管生成素- 的特異結合劑
WO2004024097A8 (en) Compositions and methods for the treatment of immune related diseases
DE69929232D1 (de) Virusähnliche partikel zur induktion von autoantikörpern
GB0209891D0 (en) Novel compounds
EP2085096A3 (de) Neuartige Zusammensetzung und Verfahren zur Behandlung von Immunerkrankungen
DE60313021D1 (de) 4-tetrazolyl-4-phenylpiperidindervate zur schmerzbehandlung
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE539084T1 (de) Promotoren zur regulierung der genexpression in pflanzenwurzeln
ATE527378T1 (de) Antisense-modulation von p38-mitogen-aktivierter proteinkinase-expression
DE602004016385D1 (de) Zusammensetzungen mit pantothensäure oder derivaten davon und ihre verwendung zur stimulierung des appetits
DK1692517T3 (da) Anvendelse af ADAM 12 til diagnosticering af præeklampsi
AU2003290939A8 (en) Replication of biological tiussue
ATE475315T1 (de) Mittel zur biologischen bekämpfung pilzlicher pflanzenkrankheiten
IL157464A0 (en) Zinc finger binding domains for nucleotide sequence ann
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
WO2005040339A3 (en) Aptamers to human epidermal growth factor receptor-3
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
DE50308032D1 (de) Isoliertes fluoreszierendes protein aus clytia gregaria cgfp, sowie dessen verwendung
WO2004074514A3 (en) Method of diagnosis of type 2 diabetes and early onset thereof
DE60336746D1 (de) Trimer-proteine zur trimer-zytokine
PL1704237T3 (pl) Ccamk biorąca udział w nodulacji i endomikoryzacji